Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2020-10-22 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated October 22, 2020, announcing that it has received a notification of intent to grant a new patent from the European Patent Office (EPO) concerning its drug AsiDNA™ in combination with PARP inhibitors. This type of announcement, detailing specific corporate developments, legal/IP updates, and often including forward-looking statements and contact information, is characteristic of a general regulatory announcement or press release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a specific announcement about intellectual property protection and not a general regulatory filing fallback (RNS) or a report itself, it most closely aligns with a general corporate update. However, given the options, it is a specific announcement about a corporate event (IP protection). It is not a Director's Dealing (DIRS), Capital Change (CAP), Dividend (DIV), or Earnings Release (ER). It is an announcement regarding a legal/IP matter. While 'LTR' is for Legal Proceedings, this is about patent *grant*, which is a positive IP development. In the context of the provided definitions, this is a specific corporate announcement that doesn't fit the primary financial reporting codes. It is best classified as a Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially related to IP/Legal matters. Given the focus on patent protection, it is a significant corporate event announcement. Since there is no specific 'IP Announcement' code, RNS (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate general classification for a press release detailing a patent notification, especially since it is not a formal financial report.
2020-10-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated October 22, 2020, announcing that it has received a 'notice of intent to grant a new patent' from the European Patent Office (EPO) regarding its drug AsiDNA™. This type of announcement, detailing a specific legal/intellectual property development (patent grant notice) rather than routine financial results (ER, IR) or mandatory filings (10-K, DEF 14A), fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the patent process were adversarial. However, since it is a positive announcement about IP protection, and it is not a standard financial report, it is classified as a general Regulatory Filing (RNS) as it is a formal, non-financial corporate update released to the public and regulators. It is not an Earnings Release (ER), Interim Report (IR), or a formal legal proceeding update (LTR), but rather a specific corporate event announcement.
2020-10-22 English
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is titled with an announcement: "Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan". It details clinical trial progress, scientific rationale, expected results timelines, and includes standard sections like 'About Onxeo' and 'Forward looking statements', concluding with 'PRESS RELEASE' and contact information. This structure is characteristic of an official press release announcing significant operational or clinical updates, rather than a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial event announcement (like DIV or CAP). Since it is a press release announcing operational progress (clinical trial milestone), it fits best under the general 'Regulatory Filings' (RNS) category, which often serves as a catch-all for official company announcements not covered by more specific codes, or potentially an Investor Presentation (IP) if it were structured as slides, but the format here is clearly a news release. Given the options, RNS is the most appropriate general announcement category for a clinical trial update press release.
2020-10-21 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release from Onxeo announcing a clinical development milestone: the recruitment of the first patient in the Phase 1b/2 Revocan study for their drug AsiDNA™. It details the study's objective (evaluating AsiDNA™ effect on PARP inhibitor resistance in ovarian cancer), provides context on the disease, includes quotes from the Chief Medical Officer, outlines the study design, and mentions expected results timing (early 2021). This content structure—a formal announcement of a specific operational or clinical update, often containing forward-looking statements and contact information—is characteristic of a general corporate announcement or press release. Since it is not a full Annual Report (10-K), a specific financial release (ER), a proxy statement (DEF 14A), or a formal regulatory filing detailing a major event like a merger (TAR) or delisting (DLST), the most appropriate classification is a general Regulatory Filing (RNS), which serves as the fallback for corporate news releases that don't fit the highly specific financial/governance categories. Given the length (over 10,000 characters) and detail, it is the announcement itself, not just a notice of publication (RPA).
2020-10-21 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2020 HALF-YEARLY FINANCIAL REPORT' and contains comprehensive financial statements, including a consolidated balance sheet, statement of comprehensive income, and notes to the financial statements for the period ending June 30, 2020. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2020
2020-09-29 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2020' (Semi-annual Financial Report 2020) for the company Onxeo. It contains comprehensive financial statements, including a consolidated balance sheet, income statement, cash flow statement, and detailed notes to the financial statements for the period ending June 30, 2020. It also includes management's discussion and analysis of the business and financial results. This fits the definition of an Interim/Quarterly Report (IR). H1 2020
2020-09-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.